To access this material please log in or register

Register Authorize

Acute coronary syndrome and remote mortality in patients with carbohydrate metabolism disorder depending on type of blood glucose lowering therapy recieved

Shashkova L. S., Kakorin S. V., Mkrtumian A. М.

Keywords: lethality, glucose tolerance disorder, acute coronary syndrome, type 2 diabetes mellitus, blood glucose lowering therapy

DOI: 10.18087/rhj.2012.6.1732

Relevance. Diabetes mellitus type 2 (DM 2) is a RF of CVD progressing. Objective. Study outcomes and complications of CHD depending on type of carbohydrate metabolism disorder, DM 2 severity, and blood glucose lowering therapy. Materials and methods. The retrospective analysis of 1220 cases both gender, who were discharged from hospital with the diagnosis of unstable angina (UA), non-Q-wave and Q-wave MI. Number of patients with normal carbohydrate metabolism was 612, with carbohydrate metabolism disorders – 608 (including patients with glucose tolerance disorder (GTD) and DM 2 of varying severity). The analysis of ACS outcomes and complications (UA, Q-wave and non-Q-wave MI, UA), 3‑year survival rate) in patients with carbohydrate metabolism disorder was carried out. Relation of glycemia levels at admission with carbohydrate metabolism disorder and blood glucose lowering therapy was analysed. Results and conclusion. In hospitalized patients with mild DM ACS outcomes and glycemia levels at admission were the most favourable, but 3‑year lethality of different reasons was the highest. The most favourable prognosis was in patients undergoing a combined therapy with glibenclamide and metformin or insulin and glibenclamide.
  1. Zimmet P, Shaw J, Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realisticview. Diabet Med. 2003;20 (9):693–702.
  2. Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26 (11):3160–3167.
  3. Аметов А. С., Соловьева О. Л. Сердечно-сосудистые осложнения при сахарном диабете: патогенез и пути коррекции. РМЖ эндокринология. 2011;27:1694–1699.
  4. Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов «Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы». www.cardiosite.ru / recommendations / 2007;146c.
  5. Franklin K, Goldberg RJ, Spencer F et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004;164 (13):1457–1463.
  6. Hasdai D, Behar S, Wallentin L et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002;23 (15):1190–1201.
  7. Александров А. А. Инфаркт миокарда и сахарный диабет: «Мюнхенский сговор», Болезни сердца и сосудов. 2007;2 (2):4–11.
  8. Bolk J, van der Ploeg T, Cornel JH et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79 (2-3):207–214.
  9. Kosiborod M, Rathore SS, Inzucchi SE et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111 (23):3078–3086.
  10. Стронгин Л. Г., Беляева Н. Г, Панова Е. И. Значение гликемического контроля в остром пероде инфаркта миокарда у больных сахарным диабетом 2 типа. Сахарный диабет. 2008;38 (1):15–17.
  11. Goyal A, Mahaffey KW, Garg J et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006;27 (11):1289–1297.
  12. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte op ReimerW, Simoons Ml: Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1‑year outcome in patient with coronary artery disease: a report from the Euro Heart Survey on diabetes and heart. Eur Heart J. 2006; 27: 2969–2974.
  13. Aguilar D, Solomon SD, Køber L et al. Newly diagnosed and previously known diabetes mellitus and 1‑year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004 Sep 21;110 (12):1572–1578.
  14. Аметов А. С., Козебубова И. В. Комбинированная терапия как особенность управления сахарным диабетом типа 2 у кардиальных больных. Болезни сердца и сосудов. 2007;2 (2):26–31.
  15. Федеральная Целевая Программа «Сахарный диабет». Методи­ческие рекомендации. Российская Академия медицинских наук. Эндокринологический научный центр РАМН. И. И. Дедов, М. В. Шестакова, М. А. Максимова. Москва 2007.
  16. Бутрова С. А., Дзгоева Ф. Х. Висцеральное ожирение – ключевое звено метаболического синдрома. Ожирение и метаболизм. 2004;1:10–16.
  17. Зимин Ю. В. Инсулинорезистентность, гиперинсулинемия и артериальная гипертензия. Кардиология, 1996:36 (11):80–91.
  18. Демидова Т. Ю. Атеросклероз и сахарный диабет типа 2: механизмы и управление. Журнал CardioСоматика. 2011;2 Доступно на: http://www.consilium-medicum.com / article / 20850
  19. Johnsen SP, Monster TB, Olsen ML et al. Risk and short – term prognosis of Myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006;13 (2):134–140.
  20. Marwick TH. Diabetic heart disease. Postgrad Med J. 2008;84 (990):188–192.
  21. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA (The Journal of American Medical Association). 2007;298 (7):765–775.
  22. Jaffe AS, Spadaro JJ, Schechtman K et al. Increased congestive heart failure myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J. 1984;108 (1):31–37.
  23. Granger CB, Callif RM, Young S et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The thrombolysis and angioplasty in myocardial infarction (TAMI) study group. J Am Coll Cardiol. 1993;21 (4):920–925.
  24. Singer D, Moulton A, Nathan D. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes. 1989;38 (3):350–357.
  25. Stone P, Muller J, Hartwell T et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 1989;14 (1):49–57.
  26. Savage M, Krolevski A, Kenien G et al. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol. 1988;62 (10 Pt 1):665–669.
  27. Jacoby R, Nesto R. Acute myocardial infarction in the diabetic patients: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20 (3):736–744.
  28. Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J. 1988;9 (3):259–264.
  29. Rytter L, Beck-Nielsen H, Troelsen S. Diabetic patients and myocardial infarction. Acta Endocrinologica 1984; (Suppl 262): 83–87.
  30. Herlitz J, Malmberg K, Karlson BW et al. Mortality and morbidity during a five year follow-up of diabetics with myocardial infarction. Acta Med Scand. 1988;224 (1):31–38.
  31. Ulvenstam G, Aberg A, Bergstrang R et al. Long-term prognosis after myocardial infarction in men with diabetes mellitus. Diabetes. 1985;34 (8):787–792.
  32. Smith J, Marcus F, Serokman R. Prognosis of patients with diabetes mellitus after myocardial infarction. Am J Cardiol. 1984;54 (7):718–721.
  33. Ulvenstam G, Aberg A, Bergstrand R et al. Long term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985;34 (8):787–792.
  34. Zuanetti G, Latini R, Maggioni AP et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22 (7):1788–1794.
  35. Capone RJ, Pawitan Y, el-Sherif N et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. 1991;18 (6):1434–1438.
  36. Bartnik M. Studies on prevalence recognition and prognostic implication. Glucose regulation and coronary artery disease. Karolinska Institutet, Stockholm 2005 (ISBN: 91–7140‑401‑5).
  37. Schramm TK, Gislason GH, Vaag A et all. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32 (15):1900–1908.
  38. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamiderelatedexcess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86 (3):247–253.
  39. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32 (1):193–203.
  40. Дедов И. И., Шестакова М. В., Аметов А. С. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа». Сахарный диабет. 2011;1 (50):95–105.
Shashkova L. S., Kakorin S. V., Mkrtumian A. М. Acute coronary syndrome and remote mortality in patients with carbohydrate metabolism disorder depending on type of blood glucose lowering therapy recieved. Russian Heart Journal. 2012;11(6):323-329.

To access this material please log in or register

Register Authorize
Ru En